Journal
BRITISH JOURNAL OF CANCER
Volume 96, Issue 12, Pages 1788-1795Publisher
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6603813
Keywords
angiogenesis inhibitors; VEGF signalling; capillaries
Categories
Ask authors/readers for more resources
Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology. These effects are typically downstream consequences of suppression of cellular signalling pathways important in the regulation and maintenance of the microvasculature. Downregulation of these pathways in normal organs can lead to vascular disturbances and even regression of blood vessels, which could be intensified by concurrent pathological conditions. These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available